ENDRA Life Sciences Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
On October 1, 2026, ENDRA Life Sciences Inc. amended its June 25, 2026 merger agreement with ASP Isotopes Inc., Renergen Limited, and related entities. Key changes: (1) LHE LNG Holdings LLC's Common Stock Purchase Warrant (1,156,774 shares) and Pre-Funded Warrant (511,541 shares)—both issued May 27, 2026—had beneficial ownership limitations removed, enabling full participation in rights offerings and distributions; (2) closing cash requirement adjusted to $3,800,002.59 less cumulative investor relations agreement payments to RedChip Companies Inc.; (3) closing board structure changed to 1 CEO director + 5+ company-designated non-executive directors + 1 PubCo director; (4) sixth addendum to ASPI Term Loan Facility Agreement (dated May 19, 2025) incorporated. Counterparty: LHE LNG Holdings LLC (warrant holder); RedChip Companies Inc. (investor relations via July 15, 2026 agreement).
Why this rating
Merger framework restructuring with $3.8M+ cash requirement is material relative to $2.7M market cap; warrant amendments reduce dilution concerns for major holder; routine governance/financing adjustments to consummate deal. Neutral impact—structural refinements to ongoing transaction, not new go/no-go risk.
Price action (we called it neutral)
before filing · preread $5.50 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.